Berardinelli-Seip congenital lipodystrophy is a very rare heterogenous disorder, first described by Berardinelli in 1954 and subsequently by Seip in 1959 (
3). It has a prevalence of < 1 case per 10 million individuals and affects all ethnic groups (
4).
Congenital generalized lipodsytrophy are caused by mutations in the AGPAT2, seipin (also known as BSCL2), LMNA, caveolin-1, and rarely the
PTRF gene. At least three loci were identified. AGPAT2 has been mapped to chromosome 9q34 and encodes the enzyme responsible for the acylation of lysophosphatidic acid into phosphatidic acid, a key intermediate in the biosynthesis of triacylglyceride and glycerophospholipids (
5). It causes BSC1; BSCL1 is less severe phenotype than BSCL2 (
6). Individuals with type 2 BSCL seem to present more severe and premature symptoms than those who have mutations in type 1 with a higher incidence of intellectual deficiency in type 2 BSCL. This is because of the variability in expression of seipin in several tissues such as liver, skeletal muscle, kidney, pancreas, testicles and a high expression in the central nervous system and AGTPA2, tissue-restricted enzyme, occurring at high levels in adipose tissue, liver and cardiac tissue, but almost undetectable in the brain (
7).
Berardinelli-Seip congenital lipodystrophy is characterized by the near complete absence of subcutaneous adipose tissue, severe diabetes mellitus, no ketosis/ketonuria and insulin resistance; the latter usually develops in the second decade of life (
8). Acanthosis nigricans, a manifestation of insulin resistance starts in childhood, becoming more severe through adolescence. It is commonly seen in flexures, sides of the neck, back and the umbilicus as grey-brown or black pigmentation with thickened skin covered by small papillomatous elevations, giving it a velvety texture. All the above three feature are seen in our patient. Similar features have been described in many other reported cases (
1,
5). Generalized lipoatrophy and insulin resistance are two of the major criteria for diagnosing BSCL (
2).
Acromegaloid features including prognathism, salient orbital ridges, enlarged hands and feet, macrogenitosomia, gigantism, muscular hypertrophy and advanced bone age, hepatomegaly and elevated serum concentration of triglycerides form the other three major criteria for diagnosing BSCL (
9). In all individuals with BSCL, the liver is affected, ranging from an abnormal liver functions to hepatic steatosis, hepatomegaly and cirrhosis. Minor criteria include hypertrophic cardiomyopathy, psychomotor retardation, hirsuitism, precocious puberty in females, bone cysts, and phlebomegaly (
2).
Other features include curly and frizzy hair, hyperhidrosis, xanthomas, hypertrichosis and different forms of nephropathy. In BSCL, apart from liver, heart and muscle, excessive fat deposition in orbit, tongue, palms, soles, breast and vulva have been documented (
10).
Cardiac abnormalities of the condition include hypertrophic cardiomyopathy, hypertension, cardiomegaly, congestive heart failure and ventricular dysfunction. Our patient showed no evidence of cardiac involvement.
Other features of this condition include empty cheeks, umbilical hernia, polycystic ovaries and pancreatic disease (loss of B cells or amyloidosis). Kher et al. has described the association of immunodeficiency in these patients (
11).
Enlarged genitalia (hypertrophy of labia majora, clitoris), signs of virilisation, precocious puberty and polycystic ovary syndrome are common and secondary to hyperandrogenism related to insulin resistance (
12).
Metabolic abnormalities in BSCL develop as the disease progress and may prove fatal necessitating optimal therapeutic and preventive measures. The prognosis of the disease is very poor, and patients often die in the third decade of life. There is no curative treatment and the current treatment options are based only on symptomatic control of the complications. Patients are advised low fat diet (< 15% of calories from fat) with enhanced physical activities. Other treatments include metformin, fibric acid derivatives, n-3 polyunsaturated fatty acids, and fish oil and leptin replacement for correction of metabolic complications (
13). Recent studies have proposed replacement therapy with leptin, a protein produced by the adipose tissue that plays an important role in glycemic control and decreasing triglyceride levels thus yielding promising results in controlling lipid and carbohydrate metabolic disorders that are characteristics of this syndrome (
14,
15). We report this case of BSCL in view of its rarity.